EWTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
46.1M
-25.5%
61.9M
+14.5%
54.1M
-3.3%
56.0M
+19.5%
46.9M
R&D
31.6M
-33.6%
47.5M
+11.5%
42.7M
-2.2%
43.6M
+16.3%
37.5M
SG&A
14.6M
+1.2%
14.4M
+25.6%
11.5M
-7.4%
12.4M
+32.1%
9.4M
Operating Income
-46143000
+25.5%
-61943000
-14.5%
-54115000
+3.3%
-55979000
-19.5%
-46858000
EBITDA
-45613000
+25.7%
-61402000
-14.6%
-53578000
+3.4%
-55454000
-19.7%
-46335000
Net Income
1.2B
+2134.2%
-57327000
-17.0%
-49013000
+2.4%
-50216000
-23.5%
-40666000
EPS (Basic)
$10.71
+2120.8%
$-0.53
-15.2%
$-0.46
+2.1%
$-0.47
-20.5%
$-0.39
EPS (Diluted)
$9.65
+1920.8%
$-0.53
-15.2%
$-0.46
+2.1%
$-0.47
-20.5%
$-0.39
Shares (Diluted)
120.9M
+12.3%
107.7M
+0.5%
107.1M
+0.9%
106.2M
+0.6%
105.5M
Edgewise Therapeutics (EWTX) — Financials